Gastroesophageal Junction Cancer
📧 Sign up to get email alerts when something new happens for Gastroesophageal Junction Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2018-03-26Clinical Trial Update: Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer [Phase 3]
A Phase 3 trial evaluating nimotuzumab plus irinotecan as second-line therapy for advanced or recurrent gastric and gastroesophageal junctio…
-
CLINICAL_TRIALS withdrawal · 2016-02-15Clinical Trial Update: Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates [Phase 1, Phase 2]
A phase 1/2 trial of Epirubicin (Pharmorubicin), Carboplatin (Paraplatin) and Capecitabine (Xeloda) for unresectable locally advanced or met…
-
CLINICAL_TRIALS withdrawal · 2015-08-26Clinical Trial Update: huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas [Phase 2]
This clinical trial update indicates that the Phase 2 study of huC242-DM4 for metastatic or locally advanced gastric and gastroesophageal ju…
-
CLINICAL_TRIALS withdrawal · 2014-08-01Clinical Trial Update: KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer [Phase 1]
This clinical trial update reports the withdrawal of a Phase 1 study evaluating KD019 in combination with Trastuzumab for esophageal, gastro…
-
CLINICAL_TRIALS withdrawal · 2012-05-28Clinical Trial Update: Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
A clinical trial on collection of biospecimens and clinical information from patients with gastrointestinal and gynecologic cancers was with…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.